Rus Eng
Main / Company's news / GEROPHARM registers a new pen injector RinsaPen I

20 December 2016

GEROPHARM to release a new reusable pen injector. The medical device has already been registered and will soon be delivered to several regions of Russia.

To date, pen injectors are among the most state-of-the-art devices for insulin injections. This is due to the fact that the form is easy to use and transport thanks to its functionality and compactness.

Creating a reusable pen injector, GEROPHARM pursued the goal to take care of the patients – it was necessary to make a pen-injector maximally convenient for injection of the medicinal product. The pen was developed in conjunction with the Ypsomed Company (Switzerland).

The new pen-injector is equipped with a mechanism for easy and convenient drug administration. The device is distinguished by an easy-to-use dose setting using the rotational movement, dose adjustment (where necessary) and activation using the start button. An important design feature is the ease of cartridge replacement, an enlarged indicator window for visually impaired patients, as well as tactile and audible feedback when setting, adjusting and administering a dose. The indicator data reflect the remaining volume of the drug, which allows to set the dose correctly up to the last unit.

GEROPHARM has been engaged in the industrial production of insulin since 2014. Rinsulin® R and Rinsulin® NPH are available in various forms of presentation – bottles, cartridges, disposable pen injectors. Currently, reusable pen injectors are delivered free of charge to the regions where GEROPHARM insulins are purchased in cartridges.

Ypsomed Group is a leading developer and manufacturer of self-administering injection and infusion systems, as well as a specialist in the treatment of diabetes mellitus with more than 30 years of experience in this field. Ypsomed is a trusted business partner of numerous pharmaceutical and biotech companies supplying pen injectors, auto-injectors, and liquid drug infusion systems. Ypsomed promotes and markets its products under the umbrella brands mylife™ Diabetescare directly to patients, through a network of pharmacies and clinics, and YDS Ypsomed Delivery Systems – to pharmaceutical companies. The head office of Ypsomed, located in Burgdorf (Switzerland), manages the company production facilities, branches and distributors. Ypsomed Group employs almost 1,300 people.

You are a health care professional?

Go up